These data suggest that the OC risk exceeds the threshold for moderate penetrance genes in RAD51C and RAD51D mutations carriers and both genes have clinical significance for diagnostic testing and preventive steps for the carriers involving both OC and BC management. The gene discussed is RAD51D; the disease is breast cancer.